OBJECTIVE: To assess the effectiveness of reduced acellular pertussis (Tdap) vaccines in adolescents and adults. SETTING: Kaiser Permanente Northern California. DESIGN: Case-control study. PARTICIPANTS: All polymerase chain reaction (PCR) confirmed cases of pertussis in members aged 11 years and older from January 2006 to December 2011. We compared the Tdap vaccination status of PCR positive cases with two control groups: people testing negative for pertussis by PCR and closely matched people from the general Kaiser Permanente Northern California population. MAIN OUTCOME MEASURE: PCR confirmed pertussis. The association of Tdap vaccination with the odds of pertussis infection was estimated by conditional logistic regression, with adjustment for calendar time, pertussis vaccine type received in early childhood, age, sex, race or ethnic group, and medical clinic. We calculated Tdap vaccine effectiveness as 1 minus the adjusted odds ratio. RESULTS: The study population included 668 PCR positive cases, 10,098 PCR negative controls, and 21,599 Kaiser Permanente Northern California matched controls. Tdap vaccination rates were 24.0% in PCR positive cases and 31.9% in PCR negative controls (P<0.001). The adjusted estimate of effectiveness of Tdap vaccination against pertussis was 53.0% (95% confidence interval 41.9% to 62.0%) in the comparison with PCR controls, and 64.0% (55.5% to 70.9%) in the comparison with Kaiser Permanente Northern California controls. CONCLUSION: Tdap vaccination was moderately effective at preventing PCR confirmed pertussis among adolescents and adults.
OBJECTIVE: To assess the effectiveness of reduced acellular pertussis (Tdap) vaccines in adolescents and adults. SETTING: Kaiser Permanente Northern California. DESIGN: Case-control study. PARTICIPANTS: All polymerase chain reaction (PCR) confirmed cases of pertussis in members aged 11 years and older from January 2006 to December 2011. We compared the Tdap vaccination status of PCR positive cases with two control groups: people testing negative for pertussis by PCR and closely matched people from the general Kaiser Permanente Northern California population. MAIN OUTCOME MEASURE: PCR confirmed pertussis. The association of Tdap vaccination with the odds of pertussis infection was estimated by conditional logistic regression, with adjustment for calendar time, pertussis vaccine type received in early childhood, age, sex, race or ethnic group, and medical clinic. We calculated Tdap vaccine effectiveness as 1 minus the adjusted odds ratio. RESULTS: The study population included 668 PCR positive cases, 10,098 PCR negative controls, and 21,599 Kaiser Permanente Northern California matched controls. Tdap vaccination rates were 24.0% in PCR positive cases and 31.9% in PCR negative controls (P<0.001). The adjusted estimate of effectiveness of Tdap vaccination against pertussis was 53.0% (95% confidence interval 41.9% to 62.0%) in the comparison with PCR controls, and 64.0% (55.5% to 70.9%) in the comparison with Kaiser Permanente Northern California controls. CONCLUSION: Tdap vaccination was moderately effective at preventing PCR confirmed pertussis among adolescents and adults.
Authors: P Plans; D Toledo; M R Sala; N Camps; M Villanova; R Rodríguez; J Alvarez; R Solano; M García-Cenoz; I Barrabeig; P Godoy; S Minguell Journal: Eur J Clin Microbiol Infect Dis Date: 2016-09-09 Impact factor: 3.267
Authors: Kevin L Schwartz; Jeffrey C Kwong; Shelley L Deeks; Michael A Campitelli; Frances B Jamieson; Alex Marchand-Austin; Therese A Stukel; Laura Rosella; Nick Daneman; Shelly Bolotin; Steven J Drews; Heather Rilkoff; Natasha S Crowcroft Journal: CMAJ Date: 2016-09-26 Impact factor: 8.262
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Anna M Acosta; Chas DeBolt; Azadeh Tasslimi; Melissa Lewis; Laurie K Stewart; Lara K Misegades; Nancy E Messonnier; Thomas A Clark; Stacey W Martin; Manisha Patel Journal: Pediatrics Date: 2015-05-04 Impact factor: 7.124
Authors: William T Shearer; Thomas A Fleisher; Rebecca H Buckley; Zuhair Ballas; Mark Ballow; R Michael Blaese; Francisco A Bonilla; Mary Ellen Conley; Charlotte Cunningham-Rundles; Alexandra H Filipovich; Ramsay Fuleihan; Erwin W Gelfand; Vivian Hernandez-Trujillo; Steven M Holland; Richard Hong; Howard M Lederman; Harry L Malech; Stephen Miles; Luigi D Notarangelo; Hans D Ochs; Jordan S Orange; Jennifer M Puck; John M Routes; E Richard Stiehm; Kathleen Sullivan; Troy Torgerson; Jerry Winkelstein Journal: J Allergy Clin Immunol Date: 2014-02-28 Impact factor: 10.793
Authors: Giovanni Gabutti; Chiara Azzari; Paolo Bonanni; Rosa Prato; Alberto E Tozzi; Alessandro Zanetti; Gianvincenzo Zuccotti Journal: Hum Vaccin Immunother Date: 2014-11-01 Impact factor: 3.452